INmune Bio Inc. (INMB)
INMBNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$1.10
-0.0400 (-3.51%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.09 -0.91%
- Market cap
- $34.05m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.07 to $1.15
- 52-week range
- $1.06 to $2.60
- Average volume
- 312.9k
- Previous close
- $1.14
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $8.00, +627.3% from here
Earnings
Next report
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.43m | -$5.47m | -$5.81m | -$1.48m |
| Net income | -$6.47m | -$5.26m | -$5.41m | -$1.27m |
News
8 latest- INmune Bio (INMB) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- INmune Bio, Inc. Enters Securities Purchase Agreement for $4.5 million Registered Direct OfferingFintel · Oct 29, 2026
- INmune Bio Establishes Global Commercialization Framework and Updates Regulatory Strategy for Ebstrocel™Fintel · Oct 21, 2026
- INmune Bio, QCi Partner To Explore New XPro Indications Using Quantum Computing; Stock Up RTTNews · Oct 14, 2026
- INmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To Board RTTNews · Sep 15, 2026
- INmune Submits EMA Regulatory Packages For Ebstrocel In Recessive Dystrophic Epidermolysis Bullosa RTTNews · Aug 27, 2026
- INmune Q2 Loss Narrows, Plans Ebstrocel MHRA Filing In Q4; Stock Up RTTNews · Aug 7, 2026
- INmune Bio (INMB) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 7, 2026
The company
INmune Bio Inc. (NASDAQ: INMB) develops medicines targeting inflammation and innate immune dysfunction. Its CORDStrom platform uses selected, pooled, allogeneic human umbilical cord-derived mesenchymal stromal cells to develop disease-specific cellular medicines. Ebstrocel (pobistrocel), the platform's lead product, is being developed as a systemic treatment for RDEB. XPro (XPro1595, pegipanermin) is designed to neutralize soluble TNF while preserving transmembrane TNF signaling. The Company's product candidates remain investigational and have not received marketing approval. Visit www.inmunebio.com for more information.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- inmunebio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.